Evidence map›Paper›PMID 12833147›Full record

ArticleOncogene2003

Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells.

Shuk-Mei Ho, Kin-Mang Lau, Samuel Chi-Ho Mok, Viqar Syed

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Inhibitory effects of Rap1GAP overexpression on proliferation and migration of endothelial cells via ERK and Akt pathways.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2011
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Shuk-Mei HoDepartment of Surgery, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Kin-Mang Lau
Samuel Chi-Ho Mok
Viqar Syed
University of Massachusetts Chan Medical School · USBrigham and Women's Hospital · USPrince of Wales Hospital · CN

Funding

CYP1A1, estrogen metabolism and ovarian carcinogenesisR01CA094221 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HO, SHUK-MEI · 2002 to 2004
$935k
Molecular Mechanism of Neoplastic TransformationR03CA091250 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SYED, VIQAR · 2002 to 2003
$159k
NCI NIH HHS CA091250NCI NIH HHS CA94221
6 · The paper itself

Abstract

Epidemiological data have implicated the pituitary gonadotropin follicle stimulating hormone (FSH) as both a risk factor for and a protective agent against epithelial ovarian cancer. Yet, little is known about how this hormone could play such opposing roles in ovarian carcinogenesis. Complementary DNA microarrays containing 2400 named genes were used to examine FSH-induced gene expression changes in ovarian cancer (OC) and immortalized normal human ovarian surface epithelial (HOSE) cell lines. Two-way t-statistics analyses of array data identified two distinct sets of FSH-regulated genes in HOSE and in established OC cell lines established from patients (OVCA cell lines). Among the HOSE cell lines, FSH increased expression of 57% of the 312 genes and downregulated 43%. In contrast, FSH diminished expression of 92% of the 177 genes in the OVCA cell lines. All but 18 of the genes affected by FSH in HOSE cell lines were different from those altered in OVCA cell lines. Among the 18 overlapping genes, nine genes exhibited the same direction of change following FSH challenge, while the other nine showed discordance in response between HOSE and OVCA cell lines. The FSH-induced differential expression of seven out of nine genes was confirmed by real-time RT-PCR. Gene-specific antisense oligonuleotides (ODNs) were used to inhibit the expression of genes encoding GTPase activating protein (rap1GAP), neogenin, and restin in HOSE and OVCA cells. Antisense ODNs to neogenin and restin, but not an antisense ODN to rap1GAP, were effective in inhibiting OVCA cell growth, diminishing proliferating cell nuclear antigen expression, and increasing caspase 3 activities. Furthermore, the ODN to rap1GAP was further shown to be ineffective in altering migration properties of OVCA cell lines. HOSE cell proliferation was not affected by treatment with any of the antisense ODNs. In summary, gene profiling data reveal for the first time that FSH may exert different biological actions on OVCA cells than on HOSE cells, by differential regulation of a set of putative oncogenes/tumor suppressors. Specifically, neogenin and restin were found to exhibit proproliferation/survival action on OC cells.

Indexed as

Gene Expression Regulation, NeoplasticAdenosine TriphosphateApoptosisCaspase 3CaspasesCell DivisionDown-RegulationEpithelial CellsFemaleFollicle Stimulating HormoneHumansMembrane ProteinsMicroscopy, ConfocalMicrotubule-Associated ProteinsNeoplasm InvasivenessNeoplasm ProteinsAdenosine TriphosphateCASP3 protein, humanCaspase 3Caspasescytoplasmic linker protein 170Follicle Stimulating HormoneMembrane ProteinsMicrotubule-Associated ProteinsneogeninNeoplasm ProteinsOligonucleotides, AntisenseProliferating Cell Nuclear AntigenRNA, Messenger

Identifiers

PMID12833147
OpenAlexW2095439647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.